The Relationship of EGFR and VEGF mRNA Expression in Ovarian Carcinoma

References

1. ↵
   1. Penson RT,
   2. Shannon KE,
   3. Sharpless NE, et al.

   Ovarian cancer: an update on genetics and therapy. Compr Ther 1998; 24: 477-487.

   OpenUrlPubMed
2. ↵
   1. Tomov S,
   2. Popovska S,
   3. Veselinova T, et al.

   Immunohistochemical analysis of epidermal growth factor receptors expression in malignant ovarian tumors [Article in Bulgarian]. Akush Ginekol (Sofiia) 2005; 44 Suppl 2: 42-47 (Bulgarian).

   OpenUrlPubMed
3. 1. Alper O,
   2. Bergmann-Leitner ES,
   3. Bennett TA, et al.

   Epidermal growthfactor receptor signaling and the invasive phenotype of ovarian carcinoma cells. J Natl Cancer Inst 2001; 93: 1375-1384.

   OpenUrlCrossRefPubMedWeb of Science
4. 1. Raspollini MR,
   2. Castiglione F,
   3. Garbini F, et al.

   Correlation of epidermal growth factor receptor expression with tumor microdensity vessels and with vascular endothelial growth factor expression in ovarian carcinoma. Int J Surg Pathol 2005; 13: 135-142.

   OpenUrlCrossRefPubMedWeb of Science
5. ↵
   1. Sini P,
   2. Wyder L,
   3. Schnell C, et al.

   The Antitumor and Antiangiogenic Activity of Vascular Endothelial Growth Factor Receptor Inhibition Is Potentiated by ErbB1 Blockade. Clin Cancer Res 2005; 11; 4521-4532.

   OpenUrlAbstract/FREE Full Text
6. ↵
   1. Hu YJ,
   2. Qu PP.

   The relationship between the expression of vascular endothelial growth factor and its receptors and the angiogenesis in epithelial ovarian cancer. Zhongguo Zhongliu Linchuang 2006; 33: 1346-1352 (Chinese).

   OpenUrl
7. ↵
   1. Fresno Vara JA,
   2. Casado E,
   3. de Castro J, et al.

   PI3K/Akt signaling pathway and cancer. J Cancer Treat Rev 2004; 30: 193-204.

   OpenUrl
8. ↵
   1. Nicholson RI,
   2. Gee JM,
   3. Harper ME.

   EGFR and cancer prognosis. Eur J Cancer 2001; 37 (Suppl 4): S9-15.

   OpenUrlCrossRefPubMedWeb of Science
9. ↵
   1. Kerbel RS.

   Tumor angiogenesis: past, present, and the near future. Carcinogenesis (Lond.) 2000; 21: 505-515.

   OpenUrlCrossRefPubMedWeb of Science
10. ↵
    1. Sonmezer M,
    2. Gungor M,
    3. Ensari A, et al.

    Prongnostic significance of tumor angiogenesis in epithelia ovarian cancer: in association with transforming growth factor beta and vascular endothelial growth factor. Int J Gynecol Cancer 2004; 14: 82-88.

    OpenUrlCrossRef
11. ↵
    1. Liang WC,
    2. Wu X,
    3. Peale FV, et al.

    Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J Biol Chem 2006; 281: 951-961.

    OpenUrlAbstract/FREE Full Text
12. ↵
    1. Jain RK,
    2. Duda DG,
    3. Clark JW, et al.

    Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Onco 2006; 13: 24-40.

    OpenUrl
13. ↵
    1. Baker CH,
    2. Kedar D,
    3. McCarty MF, et al.

    Blockade of epidermal growth factor receptor signaling on tumor cells and tumor-associated endothelial cells for therapy of human carcinomas. Am J Pathol 2002; 161: 929-938.

    OpenUrlPubMedWeb of Science
14. ↵
    1. Maity A,
    2. Pore N,
    3. Lee J, et al.

    Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidlyinositol 3V-kinase and distinct from that induced by hypoxia. Cancer Res 2000; 60: 5879-5886.

    OpenUrlAbstract/FREE Full Text